Vext Science, Inc. (CSE:VEXT)
Canada flag Canada · Delayed Price · Currency is CAD
0.3450
0.00 (0.00%)
May 1, 2026, 3:59 PM EST
← View all transcripts

Earnings Call: Q4 2025

Apr 29, 2026

Operator

Thank you for standing by. This is the conference operator. Welcome to the Vext Science Q1 and full year 2025 financial results conference call. As a reminder, all participants are in listen-only mode, and the conference is being recorded. After the presentation, there will be an opportunity to ask questions. To join the question queue, you may press star then one on your telephone keypad. Should you need assistance during the conference call, you may signal an operator by pressing star then zero. I would now like to turn the conference over to Priyam Chakraborty. Please go ahead.

Priyam Chakraborty
Company Representative, Vext Science

Thanks, operator. Good morning, everyone, and thank you for joining us today. Vext Q4 and fiscal year 2025 financial results were released earlier this morning. The press release, financial statements, and MD&A are available on SEDAR+ as well as on the Vext website at vextscience.com. We would like to remind listeners that portions of today's discussion include forward-looking statements and that forward-looking statements are included in today's filings. There can be no assurance that these forward-looking statements will prove to be accurate, or that management's expectations or estimates of future developments, circumstances, or results contained therein will materialize. Risks and uncertainties that could affect future developments, circumstances, or results are detailed in the MD&A and Vext other public filings that are made available on SEDAR+.

We encourage listeners to read those risk factors in conjunction with today's call. As a result of these risks and uncertainties, the development circumstances or results predicted in forward-looking statements may differ materially from actual developments, circumstances, or results. This call also includes non-IFRS financial information, and such non-IFRS financial measures are subject to disclosure and reconciliation included in our press release disseminated earlier today, as well as the MD&A. Forward-looking statements made during this conference call are made as of the date of this call. Vext disclaims any intention or obligation to update or revise such information except as required by applicable law. Vext financial statements are presented in U.S. dollars, and the results discussed during this call are in U.S. dollars. I will now pass the call over to Eric Offenberger, Chief Executive Officer of Vext.

Eric Offenberger
CEO, Vext Science

Thanks, Priyam. Good morning, everybody, and thank you for joining our Q4 and fiscal year 2025 financial results conference call. I'm joined today by Trevor Smith, Vext CFO. 2025 was a year of solid execution and meaningful transition for Vext. We made important progress across both of our core markets while continuing to build and organize the business for the next phase of growth. The key takeaway from the quarter and the year that our strategy is working. As we've said consistently, our focus on owned retail gives us greater control over the customer experience and supports cash flow generation over time. We've been focused on building a retail-led platform, and in 2025, that focus translated into strong revenue growth, improving cash generation, and record operating cash flow.

In the Q4, revenue was $13.7 million, up 35% year-over-year, with operating cash flow of $3.2 million, driven by continued strength in Ohio. For the full year, revenue grew 43% year-over-year to $51.4 million, and we generated $11.7 million in operating cash flow, up 256% year-over-year. I want to address Q4 EBITDA directly. Reported Q4 EBITDA was -$3 million, reflecting a $5 million non-cash impairment on one of our Columbus, Ohio dispensaries. The impairment is primarily driven by revised cash flow expectations following significant growth in competing dispensary counts in the Columbus market since our original acquisition, and not by the store's operating performance, which remains at the state per store average. Excluding the impairment, Q4 adjusted EBITDA was $2.1 million.

The underlying performance of the business remains strong and continues to reflect the effectiveness of our retail strategy. What stands out to me is that we delivered this performance while operating across two very different markets. Navigating both with discipline isn't easy, and I'm very pleased with how our team executed across both this year. Turning first to Ohio. Ohio continues to be the primary growth engine for Vext and a key driver of our financial performance. 2025 marked the first full year of the adult use market in the state, with total cannabis sales exceeding $1 billion statewide.

While the competitive landscape expanded meaningfully, with the number of licensed dispensaries increasing by nearly 50% over the course of the year, Ohio remains a highly controlled and structurally defensible market with a capped retail model, disciplined rollout of new stores, and regulatory safeguards that support long-term pricing and margin stability. Within this framework, we continue to see a clear opportunity to scale our presence with high-quality retail locations. We made significant progress expanding our retail footprint in 2025, growing our Ohio retail presence from two stores to five operational locations. During the year, our Ohio retail operations accounted for over half of consolidated revenue, with sales increasing over 120% year-over-year. The majority of our stores performed at or above the statewide per store average.

Looking ahead, our focus is on completing our build-out to the eight-store license cap. We expect to open our sixth location in the Q2 of 2026. We are particularly excited about this Fairfield location, which is positioned in a high visibility quarter and includes a drive-through format that has already been well received at some of our other stores. We expect Fairfield to ramp efficiently and become a meaningful contributor to revenue and cash flow as it stabilizes. Beyond that, our seventh location is currently under construction and expected to be operational end of 2026, with an eight and final location anticipated to open in early 2027. As these additional doors come online, we expect them to further support revenue growth, operating leverage, and cash flow generation across the Ohio platform.

As we complete the Ohio retail expansion, we are actively redeploying capital toward vertical integration and cultivation expansion to support that network.

This includes advancing plans to expand cultivation capacity at our Jackson facility and further develop our manufacturing capabilities. Overall, we believe Ohio provides a clear path to scale within our existing license structure. Turning to Arizona. Arizona remains a mature and competitive market, with continued pricing pressure driven by excess supply. In fiscal 2025, total cannabis sales in the state declined approximately 3%, while average item prices were down 7%-8% year-over-year. Despite this backdrop, our performance remained resilient. Our retail locations performed above the statewide per store average for most of the year, supported by strong cultivation yields and disciplined execution across the business. That said, the fundamental economics in the Arizona cultivation market are clear, and we are taking decisive action. As announced in March, we are transitioning to a lean retail-first model in Arizona.

This includes exiting cultivation through the shutdown and decommissioning of the Eloy facility during the Q2 of 2026. The property will then be marketed for sale, with proceeds expected to reduce debt and further strengthen the balance sheet. Third-party supply will begin replacing Eloy output in the middle of the Q2, with the full transition reflected in the Q3, which is a seasonally slower period in Arizona and aligns well with the timing of this shift. We expect that this shift will remove the internal sell-through constraints that impacted pricing and product mix in 2025. Going forward, Arizona will be focused on maximizing performance at our two Phoenix area dispensaries while expanding our manufacturing and distribution capabilities through a more capital-light model, including third-party distribution and contract manufacturing.

Arizona will be operated with a focus on cash generation and margin optimization rather than capacity investment.

We also continue to evaluate disciplined M&A opportunities with a focus on strengthening our position in core markets and maintaining flexibility to pursue opportunities that meet our return thresholds. As we look ahead to 2026, we are entering the year with a more focused footprint and a clear capital allocation framework. Our priorities are straightforward, completing the Ohio retail build-out, expanding cultivation capacity to support that network, and continuing to optimize our Arizona operations. With capital directed toward our highest return opportunities, we expect to drive continued margin expansion, strong cash flow generation, and long-term shareholder value. Before I close my remarks, I would like to note last week's announcement from the DEA regarding the reclassification of state licensed medical cannabis at the federal level.

While still early, this represents a constructive step that could support both efficiency and better access to financing for solid players in the industry, while further aligning federal policy with the framework already established across many states. Our view internally is that it will continue to be a state-by-state market, but this news was a long time coming and a step in the right direction. With that, I'll turn it over to Trevor for a closer look at the financials. Trevor?

Trevor Smith
CFO, Vext Science

Thank you very much, Eric. Overall, 2025 was a year of strong financial performance for Vext, marked by meaningful revenue growth and a significant step-up in operating cash flow as the business scaled. Starting with the Q4, revenue was $13.7 million, up 35% year-over-year and up 8% sequentially, reflecting continued contribution from our expanded Ohio retail footprint. Operating cash flow was $3.2 million, an increase of $1.9 million sequentially, with cash flow margin improving to 23%. This reflects strong underlying performance and improved conversion of earnings into cash as the business scales. Adjusted EBITDA in Q4 was $2.1 million, reflecting inventory accounting impacts related to pricing pressure, particularly in Arizona, which are expected to normalize as that inventory turns.

Operating cash flow provides a clear view of the underlying performance for the quarter. Turning to the full year 2025. Revenue was $51.4 million, up 43% year-over-year. Growth was primarily driven by Ohio, including the consolidation of three additional dispensaries and the first full year of adult use sales, which more than offset pricing pressure in Arizona. EBITDA was $5 million for the year, representing an increase of $7.2 million year-over-year and a return to positive EBITDA. Adjusted EBITDA was $10.9 million, up approximately 21% year-over-year. The 2025 annual adjusted EBITDA margin was also 21% compared to 25% in the prior year. The year-over-year decline in adjusted EBITDA margin primarily reflects pricing compression in Arizona, which reinforced our decision to exit cultivation in that market to focus on retail.

Operating cash flow was $11.7 million, up 256% year-over-year. The 2025 cash flow margin also improved to 23% of revenue, compared to only 9% in the prior year. The increase in cash flow margin reflects the shift towards a greater mix of retail sales, disciplined cost management, improved cultivation yields, and improving operating leverage as the platform scaled. There are a few items worth highlighting to help frame these results. In the Q4, we recorded a $5 million impairment related to our Columbus, Ohio dispensary, including $3 million of goodwill and $2 million of intangibles. This reflects a balance sheet valuation adjustment and not the store's underlying operating performance, which remains at the state average.

We also recorded an increase in our uncertain tax position to approximately $8.1 million at year-end, following a restatement of prior periods to reflect previously understated balances. This resulted in the recognition of a UTP liability of approximately $5.5 million as of January 1, 2024, and a $7.7 million as of December 31, 2024, including the reclassification of approximately $5.3 million from income taxes payable and accrued liabilities with a net incremental liability of $2.4 million recorded through opening retained earnings. I would like to highlight that this was a balance sheet-only adjustment with no impact on cash, revenue, gross profit, net loss, or earnings per share for any period. The increase reflects updated estimates of potential interest on certain tax periods and resulted in higher interest expense in Q4 2025.

We note these items remain under audit and subject to change. As Eric outlined, the DEA issued a final rule to reschedule certain state-licensed cannabis products to Schedule III on April 23rd, which included a recommendation for retroactive tax treatment under Section 280E. For context, Arizona operated as a medical-only market through 2020, and Ohio was medical only through the Q3 of 2024. If enacted, we believe a substantial portion of the periods reflected in our own uncertain tax position would fall under the medical use window, and the recommended retroactive relief could result in a material reduction in the liability over time. The company will recognize any financial impacts of this rule, including any retroactive relief, when the tax authorities enact or clarify the recommendation by the DEA.

No financial impact from this rule was recognized in the 2025 statements.

Additionally, we made certain classification updates between cost of goods sold and operating expenses in consultation with our auditors and advisors. These changes had no impact on prior period results, and comparative figures remained unchanged. Taken together, these items are primarily non-operating and do not impact our view of the underlying financial performance of the business. Operating expenses increased approximately 31% year-over-year, primarily as a result of the previously mentioned $5 million impairment related to the Columbus, Ohio dispensary. Excluding that one-time event, operating expenses were relatively stable and actually declined as a percentage of revenue. On the balance sheet, we ended the year with approximately $5.1 million in cash and continued to reduce debt during the period, reflecting our focus on strengthening the balance sheet through ongoing cash generation.

Reported working capital at December 31, 2025 was negative, primarily driven by the $8.1 million uncertain tax position I just mentioned. IFRS requires this item be classified as current, even though the timing of repayment is uncertain, particularly in light of the previously mentioned DEA rule. Overall, the business continues to perform well. We are scaling our retail platform, beginning to see operating leverage and generating strong and consistent cash flow. With a more focused operating structure and capital directed towards our highest return opportunities, we believe we are well positioned to continue driving these metrics higher in 2026. Thank you everyone for joining us for our Q4 and fiscal year 2025 financial results conference call. I'll now turn it over to the operator for your questions.

Operator

We will now begin the Q&A session. To join the question queue, you may press star then one on your telephone keypad. You will hear tone acknowledging your request. If you're using a speaker phone, please pick up your handset before pressing any keys. To withdraw your question, please press star then two. We will pause for a moment as callers join the queue. The first question today comes from Pablo Zuanic with Zuanic & Associates. Please go ahead.

Pablo Zuanic
Managing Partner, Zuanic & Associates

Good morning, everyone, and congratulations on the free cash flow performance. I think that on market cap, that's about a 15% free cash flow yield. I mean, that's a very attractive number. Look, on the retail front in Ohio, I have two questions. One, more Macro about the market. Yes, we're seeing this growth in the number of stores that's ahead of the actual market growth in terms of sales, but that seems to be a bigger deal in the bigger cities than in the more college, you know, rural areas or smaller towns. Please correct me if I'm wrong, but I see you're taking this ride down on the Columbus store, but you're not adjusting or doing ride downs on your other four stores, right? That's the first question, more at a macro level.

Then the second question, if you can just give more of an update on your five stores in terms of, you know, their competitive position. I know you're talking about you're performing in line or above the market average in terms of revenue per store. As we know, that market average has been coming down, right? Your retail sales were up, I guess they are outperforming. If you can just give more color about the five stores in terms of competitive landscape. Thank you.

Eric Offenberger
CEO, Vext Science

Yeah. Let me try to frame that a little bit for you, Pablo, good morning. For us, the Columbus store is the one that had the biggest competitive thing. I think your assessment of the market's correct. You know, that's where people tend to gravitate towards. Obviously, the stores that are not in those situations are not getting the competitive pressure, and we don't have any, you know, impairment related to it, period. The other thing it also is, you know, the Columbus store was something we didn't buy as part of a normal negotiation. It was part of the acquisition of the, our partner buyout in Ohio. That was something negotiated quite a while ago before you started seeing the landscape.

I think that was part of it too, is, you know, as things develop, you get more clarity to it versus what it looked like, you know, six years ago type of thing. I think that's also impacted the Columbus store. We think that that's gonna continue to go and continue to develop and, you know, those stores will get all built out and get caught up and everything starts to shift. We've always been focused on, you know, as we said, of selling our product through the stores. We like the rural stores, we like those locations because it makes it a little bit easier for us to, you know, reflect solid market performance. That's how I'd answer that question.

I don't know if Trevor would give you any more color on the first stores, but when we say in the reports that the majority of them are above state averages, the ones that are lower than state average, we still get a good return on our investment and return on assets is how we look at it. We don't really focus as much on the top line. We know that the market likes to look at that. We look at what cash we're generating through the store and what profit.

Pablo Zuanic
Managing Partner, Zuanic & Associates

Okay. Thank you. Just to follow up on the three next stores to open, I know you said Fairfield in the Q2 sometime. That was supposed to have opened, I think, in the Q4 last year. If you can just give more color about the delays there. On stores number seven and eight , that's Columbus and Cincinnati. I mean, traditionally, you focus again more in the smaller towns, rural areas, right? You're seeing more competition on the bigger cities. Should we be concerned about store number seven or number eight? Is there room or leeway to relocate those stores? Thank you.

Eric Offenberger
CEO, Vext Science

Okay. The, the issue with the store in Cincinnati that we did plan on opening in the late year is, candidly, I didn't realize that asphalt companies close in Ohio during the winter, and you can't pour asphalt. That's really the delay there, is we're still getting pavement put in and the asphalt laid down in that location. You're very weather dependent on that. That's what's been the biggest delay there. The store's ready to go. Everything's in. We cannot call for inspection from the state until we have the certificate of occupancy, and we cannot get the certificate of occupancy until the paving's done. They've been working on it, finishing it. We expect in the next couple weeks that'll be done, then we can call for the state inspection.

That store, based upon where it's located, it's in a prime area, as we've talked about, and has a lot of traffic area. When we're looking at a major, you know, being in a bigger market like we've talked about, if we're locating the store, not something we bought, we look at what the traffic patterns look at, what the surrounding areas look like, and if they are preventing dispensaries from going in. On Columbus, that's what we're doing on the second story. It's right off of a major belt on the freeway. It's in a good community area, and one of the townships right next to it has got a moratorium on dispensaries. Those people are traveling. We're gonna be a convenient travel for them, and as I said, it's off of the beltway.

In that city, it'll have a drive-through access to it, something we couldn't do on our existing Columbus store. That wouldn't work. Same thing on the second Cincinnati store. Depending on what the zoning looks like, it potentially could be adjacent to our retail similar in Cincinnati now with the large retail chain that we're working with there. We're trying to see if we can't put another store on that existing property or the other community that we're looking at and working with, trying to get through zoning there has been the challenge. It's on a major thoroughfare and has good traffic access, a good pattern, and they've limited their license. When you say Cincinnati, it's really like a suburb of Cincinnati.

We think those two stores are gonna perform well depending on where they go within those three locations.

Pablo Zuanic
Managing Partner, Zuanic & Associates

Thank you. Let me just have a couple of more, if I may. One, just bigger picture regarding Ohio. I think in the Q3 last year, pre-rolls were allowed, right? I think the purchasing limit per consumer was also increased. Have we seen a pickup in the market? I guess to some extent we're still awaiting the adult use rules, right? It's still called non-medical. If you can just give some more color in terms of bigger picture on Ohio in that way. Thank you. I'll follow up with another one.

Eric Offenberger
CEO, Vext Science

Yeah, I think you got some clarity on some of that stuff too. You know, surprisingly, the pre-rolls haven't taken off for us like they have in other markets. People are still buying the flower, you know, edibles still do well in Ohio comparative to like Arizona for us as a percentage. You know, different methods of consumption. As far as the rules, I think there's got a lot of clarity coming out. The state's got some new rules coming in with labeling and stuff along those lines that take effect all the way in September, changing how you do the product setups and some clarity there. We're still seeing that, and they're changing some of the dosing that you can buy on adult use and what the quantities are.

We're now doing, you know, eighths in that market instead of the tenths like we were doing in that market. That's been a switch over for us, which has, you know, been nice to get that so you're, you know, it's a little bit easier on the business. Some of those things are coming in. They've at least lightened up the advertising a little bit. We can put a sign up on the store, you know, that type of stuff. You know, we're doing all those things. The biggest thing we're doing in Ohio, Pablo, on the existing stores is getting the drive-throughs into them of where we can. The Jeffersonville store's drive-through should be opening any day. The Athens store is under construction. We hope to have that open in a few in the next month.

We think that's really the key, is that convenience, you know, of popping that consumer in and out of that store as quick as we can and align the delivery method for them to be more traditional.

Pablo Zuanic
Managing Partner, Zuanic & Associates

Thank you. One very last one. I mean, obviously we only had the final order from the DOJ just come out last week, right? I know it's too early to tell a lot of things. In your opinion, are M&A discussions picking up or no change? I'm referring to the comment you made, right? That you may look at more stores in Arizona, and perhaps entering other states or even, you know, Vext start partnering with another company, in some form of merger. What color can you share about your expectations about how M&A plays out given all this positive backdrop on the regulatory front at a federal level, national level? Thanks.

Eric Offenberger
CEO, Vext Science

I think that there are a lot of places, you know, a lot of people have these uncertain tax provisions and stuff along those lines, and you look at some of the concentration of states that they were selling into. You know, if that Department of Justice recommendation into Treasury becomes law and retroactive, then you are going to have a lot of people sitting with a lot of cash on their balance sheet, and I'm sure that they will start looking at, you know, ways to deploy it. What I think will be different, though, on this one, Pablo, is that people will be looking not at unreasonable multiples and be looking at more of operational type of things versus in the past where they were trying to scale up to size and top line.

They'll be looking at where contribution can be and, you know, how much are you gonna take on a drag, you know, of past sins, as I'd call them, on their balance sheets of what they're acquiring. I think you'll see some of that. That'd be a natural to me. I think it'll take a little bit of clarity. You know, I don't think anybody's gonna wanna jump out and say, "Okay, we're gonna get retroactive," without the IRS saying that. I think that's one issue. I think from our perspective, and again, who knows, but, you know, Trevor and I, as we talked in the past, you know, we're actively doing audits with the IRS on our stuff, you know, and have audits open through 2023, as we've disclosed previously and talked about.

You know, those are always a negotiation and going back and forth of what's allowable, what's not allowable, and it's a long process. We're hoping that there be more clarity to the process and that, you know, the agents will start to get some clarity internally so it's not like, you know, consistently renegotiating. You know, we're dealing right now with three or four different agents on the same files because they switch off and stuff like that, so that's where you get some of this inconsistency and that's really challenging. You know, as Trevor mentioned in our notes, you know, that's why we end up with, you know, having to do a restatement and stuff along those lines. We get more clarity as we go. Hopefully, this will help with that too.

I see that's a real positive. I see the other side on that as a positive, and absolutely you'll see more M&A activity and, you know, whether you are acquiring, you know, merging or doing whatever you say, you know, there's going to be more capital available and, it'll be a different look this time. I think it'll be more, more accretive to the shareholder and not this large buy at all cost type of thing.

Pablo Zuanic
Managing Partner, Zuanic & Associates

Right. Thank you. That's good color. Thank you.

Operator

The next question comes from Paul Penney with Partner Capital Group. Please go ahead.

Paul Penney
Managing Director, Partner Capital Group

Thank you. Hey, Eric. Hey, Trevor. Good morning.

Eric Offenberger
CEO, Vext Science

Morning.

Paul Penney
Managing Director, Partner Capital Group

With the cultivation-like strategy in Arizona, what are your, you know, long-term and near-term margin expectations? Specifically. Like, what is your average cost to produce these days per pound? Compare that directly with what is third party biomass spot price and so forth. What's that, what's that variance or margin today?

Eric Offenberger
CEO, Vext Science

Without giving you specific numbers, because we don't really do that and haven't historically done that. As Trevor's mentioned, you know, Trevor and the team have done a really good job on this. I wanna make sure everybody understands what happened in Arizona. The yields continued to go up. The quality continued to go up. They were really doing a great job, and that's really held us into this position for where we were for the last couple of years as we watched the market continue to decline in Arizona. We really didn't expect it would continue to decline, but it did. As it declined, we're producing at about what we consider, like, an average indoor grow cost somewhere in the, you know, mid $300s.

I think that's pretty realistic across the market and, you know, in that. Then once you do it all baked in on a return on investment and stuff like that, you're in the, you know, $800 range to, you know, $850- $900, depending on how your cost of capital is as a company. I think that's pretty realistic, and I think anybody telling you different, I'd like to see their books. That seems to be where that falls into place. What happens is in the marketplace, like Arizona with the overhang, it's a typical supply demand thing. On the wholesale thing, they're trying to move volume, so there's people trying to make payroll. They will discount basically to cash or below cash, recuperating costs that are five months old in what they spent on cash.

From our perspective, that marketplace tells you that you don't really want to be in that production thing as it's going through its process. The way we structure our asset base, it's more lucrative for us to redeploy that capital. That was the decision that was made on that. Again, it's not a reflection on what the quality was or the cultivation. It's a reflection on the market. We go to market believing we don't set the market, we participate in it. We look at what's the opportunity in the market and where can we fit in. That's where we fit in. You basically have to get out of the cultivation business.

Paul Penney
Managing Director, Partner Capital Group

Sure. That's great. I understand. Are there any, you know, just any interesting dispensary acquisitions out there that make any, you know, economic viability? I know expectations have been lofty in the state despite the challenges. Are you seeing any change there?

Eric Offenberger
CEO, Vext Science

Not really. I mean, I think the value of the license is still really there. Candidly, Paul, as you look at it, if you're Vext and you look at your value of your license, we've always said that the cultivation is almost like a negative, it's a drag. Let's say your cultivation license or your dispensary license is worth X. If you have a cultivation, that's X minus Y. You really have to deal with that cultivation to unlock your value as that market consolidates because supply is out there. If you're an acquirer, why would you wanna do that and have extra supply? You have to deal with it and what the liquidation is and everything like that. Fortunately, the way we've done our assets, you know, we're gonna deal with our cultivation.

We think that that should give us a premium on what happens in Arizona, and we're pretty optimistic that our results from Arizona go up both on an EBITDA basis and on a cash flow basis. That's kind of our impression. We've become a lot more nimble in the market and a lot more flexible. If you're not gonna have tremendous scale, you better be damn nimble or you're not gonna survive it. That would be my color. I think Trevor's got some, you know, color on that too. I'd like his input on this question.

Trevor Smith
CFO, Vext Science

Good morning, Paul. The decision to close Eloy was not an easy one. The team did just such a hell of a job performing and improving performance over time, and we saw even a pathway to continue to make, you know, some capital light investments to further improve performance. At the end of the day, the macro was too much to ignore, the redeployment of capital into more accretive opportunities, particularly as Ohio continues to scale and expand, as we've disclosed, it was just too much for us to ignore, that's why the decision was made.

Paul Penney
Managing Director, Partner Capital Group

Totally get it. Very smart, actually. Then just a couple of houseclean-cleaning items in Ohio. Do you expect any other impairments, just to be clear, in the state? Then, secondly, of the eight stores, how many do you expect will have drive-throughs?

Trevor Smith
CFO, Vext Science

No. To be totally clear, as we mentioned in the filings, no additional impairment is expected in Ohio or any other location. This includes the Arizona licenses. No impairment was taken on Eloy. We'll have more updates as that sale process continues, but no reason to expect any impairment there. I believe the drive-through number, only the Columbus store that we took the impairment on, is not able to have a drive-through, which is certainly impacting the future cash flow forecasts from when it was originally acquired and perhaps a driving force towards the impairment we took in Q4.

Paul Penney
Managing Director, Partner Capital Group

Great. Thanks, guys. Good work.

Eric Offenberger
CEO, Vext Science

Thanks, Paul.

Operator

Once again, if you have a question, please press star then one. The next question comes from Josh Felker with CB1 Capital. Please go ahead.

Josh Felker
Research Analyst, CB1 Capital

Hey, good morning, guys. Congrats. Really strong performance there. Few questions. I'll stick with Ohio to start. You mentioned last quarter a few ongoing pilot programs to boost operating efficiencies. Just wondering when will we know the results of those programs, and do you now have any clearer line of sight on potential benefits derived from those programs yet?

Eric Offenberger
CEO, Vext Science

Trevor, that's probably yours.

Trevor Smith
CFO, Vext Science

Yeah. We mentioned the sharp improvement in yield. I think you saw that in the note six of the financial statements under biological assets. We disclose grams per plant. That went up significantly in Q4. We're happy to report it went up again, high single digits again in Q1. We're expecting further increase in yield is gonna be the biggest driver. That is gonna fuel, you know, supply in the market and any, you know, potential weakness from additional stores opening before we can get ours open. It's gonna be offset by additional wholesale because Ohio is very much the cultivation-led business with trying to pair to retail. Anytime cultivation gets ahead of retail, we have that wholesale channel to offload, and then obviously wanna get our own retail back in to re-recover that additional supply.

I'd say that's the biggest one. The other pilot programs, to drive, you know, performance in Ohio are certainly gonna be those drive-throughs. Really excited about the Athens drive-through in particular, as well as the drive-through in the new Fairfield location once it gets open. Those are two, Athens already is a great performer, and then Fairfield is expected to be great even ahead of that. We think those in addition to cultivation yields are gonna be the biggest performers for Ohio in 2026.

Josh Felker
Research Analyst, CB1 Capital

Fair to assume a little less than a pilot program, a little more of an operating strategy that you've already cleared and they've already approved of. Understood. Trying to break down Ohio revenue composition going forward. As you just noted, Trevor, obviously the wholesale market is going to be a larger part until those doors come online. You noted last quarter the increase from Ohio supply will boost wholesale sales until your new stores come online. Just interested in what percentage of the existing facility is sold in the wholesale market today. With the Jackson expansion plan, I'm just wondering, once that's fully online, how much additional capacity do you think you'll possess beyond what you will require to service your own eight doors?

Trevor Smith
CFO, Vext Science

It's a give and take. I hate to dodge your question. I'll give you a straight answer, but there's a lot of assumptions, you know, how quickly does the yield come up? How quickly do the stores come up? You know, our view is we always are gonna try to maximize that yield. As the yield comes down, we look for the distribution internally, how are the stores doing, the drive-throughs, the new stores. It's something we actually as a leadership team stay on very, very close and make quick decisions, but certainly as close to real-time decisions on pricing and availability for wholesale as many times as we can for the state of Ohio. It's gonna be a give and take through 2026.

The additional expansion plans also need to be approved by the state. I'll wait to comment on additional capacity, but we certainly have line of sight into continued growth in that market. Our overall strategy of trying to stay 70%-80% vertical has not changed.

Josh Felker
Research Analyst, CB1 Capital

Just interested in how no cultivation impacts Arizona strategy. I know you still have the manufacturing operations outside of Eloy. It still sounds like you'll run those operations, and it still sounds like you'll service those manufacturing-derived segments. Just wondering, is all of that correct? Those segments are typically higher margin versus flower-focused segments. Can I correct that understanding for Arizona?

Eric Offenberger
CEO, Vext Science

Yeah, Josh, yeah, I think you're clear on that. Really the manufacturing that we're doing in Arizona is we have some, you know, relationships with people that we do manufacturing for. I think we'll continue to do that. You know, it's just a real light and light touch, so the expense structure is not that heavy on it. It kinda gives you the insurance on the back end. If cultivation was to change, we do have some cultivation asset in that area that could match demand in those stores if we needed it. If there was a fire or some natural disaster, we could stand up cultivation relatively quick and not have a, you know, a heavy cost structure. It is more of the insurance to it too. That, that said. We're, we're gonna be in a market.

The way we really look at it, Josh, is we think that the space that you have to look at in this industry is not necessarily marketing but merchandising. You're really merchandising your product. It's not like I'm trying to create a demand. I'm trying to move that demand through a retail channel as quick as I can, as efficiently as I can, and you line up your manufacturing to back it. That's why we don't see it like we're trying to entice somebody to use cannabis as far as your marketing. You're more in trying to merchandise it like traditional consumer products or something along those lines. Then we think there's a distinction, and that's really the way we try to go to market on the retail side.

With that said, that's why we, you know, looked and said, okay, the manufacturing makes sense because we're really doing a contract on the OEM side and white label, and we do that efficiently. There's a need in the marketplace because there's so much capacity on the cultivation side that it'll line up and you've got your retail store you can do some of that through, plus you have the alignment, and now you switch too, because you become more of a shelf space for somebody that's doesn't have that distribution channel, so you can really line it up. We think it's going to be significantly improved for our position and for our consumer base when we're merchandising to them and gives us a lot more flexibility. That would be my comments.

I think Trevor might have some other color on it.

Trevor Smith
CFO, Vext Science

Yeah, just to clarify, Josh, manufacturing is in a facility in Phoenix, so it will not be impacted by the Eloy closure. Other than, you know, obviously the trim being produced at that facility won't be available for processing, but the fact we're closing the facility due to oversupply tells you we're not concerned about acquiring input material for the manufacturing team.

Josh Felker
Research Analyst, CB1 Capital

Yes. Love it. Apologies, I'm gonna sneak this in as a third question. I'm just wondering how large is the competitive advantage for drive-throughs in Ohio? Are competing dispensaries around you also equipped with drive-throughs, or do you think you'll be able to capture some of those consumers by having that offering when other dispensaries don't?

Eric Offenberger
CEO, Vext Science

The Columbus one on the main drive, the competing dispensaries that are really close to it, one of them has a drive-through, a couple of the others don't. You're kind of in a residential area and all street parking, paying that kind of stuff is the problem with that one, Josh, and you can't really fit it in. If you could send stuff through a pneumatic tube or something along those lines, you could probably get away with it like a bank, that's not allowed at this point in time, you really can't configure it. The other stores right now are more of the rural stores, it's a big benefit, you know. It's not a benefit because competition's there or doesn't have them. You have less competition and less density, right?

It's more of you're hitting somebody with the convenience factor and stuff along those lines. In Arizona, we did that with, like, walk-up windows inside of the dispensary. You're technically getting your cannabis in the dispensary, but you're really going through a window, so you can bypass the reception, you can bypass all that check-in, you know, like the speedy window or Speedy Weedy. You know, that type of concept. When you get to Ohio, we think the drive-throughs really are big. When we get to Cincinnati, we see that's going to be really big because of what, as Trevor Smith's mentioned before, the unique part of that store right now is it's at a large area with a lot of traffic, and we're in a area where there's a large box anchor that sees a lot of traffic.

We think just by geographics and being close to it, if you have a convenient in-and-out way, you get that convenience purchase. We think that's a good purchase to have, and that's an easy way to get those people passing through that drive-through.

Josh Felker
Research Analyst, CB1 Capital

Super. Really appreciate the color. Congrats on the quarter. Thanks, all.

Eric Offenberger
CEO, Vext Science

Thank you.

Operator

This concludes the Q&A session and today's conference call. You may disconnect your lines. Thank you for participating, and have a pleasant day.

Powered by